Aurobindo Pharma has received approval from the US health regulator to manufacture and market generic Voriconazole tablets used for the treatment of fungal infections. The company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Voriconazole tablets in the strengths of 50 mg and 200 mg, Aurobindo Pharma said in a statement. It expects to launch the product, generic version of PF Prism C V’s Vfend tablets in the same strengths, by March end. “The approved product has an estimated market size of USD 103 million for the twelve months ending November 2015 according to IMS,” the company said. Aurobindo has 233 Abbreviated New Drug Application (ANDA) approvals, (202 final approvals including 10 from Aurolife Pharma LLC and 31 tentative approvals) from USFDA. Aurobindo Pharm stock price On January 27, 2016, Aurobindo Pharma closed at Rs 801.85, down Rs 16, or 1.96 percent. The 52-week high of the share was Rs 891.50 and the 52-week low was Rs 490.50. The company’s trailing 12-month (TTM) EPS was at Rs 25.26 per share as per the quarter ended September 2015. The stock’s price-to-earnings (P/E) ratio was 31.74. The latest book value of the company is Rs 94.54 per share. At current value, the price-to-book value of the company is 8.48.
- Sensex Ends Flat Ahead of Derivatives Expiry
- As China Tries to Reassure on Yuan Stability, Investors See Depreciation